Fontem US, Inc. issued the following announcement on May 1.
Fontem US, Inc. (Fontem), leader in next generation nicotine products and marketer of blu™ electronic cigarettes, submitted comments to the Federal Register docket on the FDA’s recent draft guidance related to certain “deemed” tobacco products, including electronic nicotine delivery systems (ENDS). The comments reflect Fontem’s and blu’s support of the agency’s stated goals of clearing a path for those adults who want to reduce use of combustible tobacco products while simultaneously keeping nicotine-containing products out of the hands of youth.
“It is wholly unacceptable that in the last three years, 10% more cigarette smokers think vaping is as hazardous as cigarettes. Bad actors, unchecked retailers, and unclear regulations have not only damaged the entire category, but they are also preventing people from making informed choices,” said Antoine Blonde, U.S. General Manager for Fontem. “At Fontem, we are consistent and clear that all ENDS are only intended for adult smokers. We believe we offer a better alternative to cigarettes and are committed to preventing youth access and use. Our comments offer a sound and balanced way forward,” continued Blonde.
In addition to offering support for FDA proposals, the comments provide the agency with additional scientific data and literature, including details regarding Fontem US’s four-part Youth Access Prevention Program. The comments also identify certain concerns regarding the FDA’s approach to regulation, specifically regarding the treatment of flavors, which have been scientifically shown to play a central and important role in achieving the FDA’s goal of migrating cigarette smokers to potentially less harmful nicotine products like ENDS.
To read the comments in full, please click here.
Original source can be found here.
